From: Aldolase predicts subsequent myopathy occurrence in systemic sclerosis
N° | Type | Antibody | At baseline | At diagnosis | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aldolase (0 to 7 U/L) | AST (0 to 32 U/L) | ALT (0 to 32 U/L) | CK (0 to 160 U/L) | 8MMT (0 to 80) | Aldolase (0 to 7 U/L) | AST (0 to 32 U/L) | ALT (0 to 32 U/L) | CK (0 to 160 U/L) | EMG | Thigh muscle RMI | Muscular biopsy | |||
1 | dSSc | ATA | 16 | 38 | 12 | 34 | 66 | 19 | 172 | 49 | 800 | + | - | + |
2 | dSSc | ATA | 9 | 35 | 20 | 11 | 60 | 9.7 | 58 | 28 | 234 | + | - | + |
3 | lSSc | ACA | 15.8 | 36 | 24 | 25 | 64 | 40 | 86 | 32 | 100 | - | + | + |
4 | lSSc | ATA | 23.5 | 25 | 31 | 31 | 55 | 9.3 | 53 | 25 | 364 | + | + | + |
5 | lSSc | ACA | 29 | 55 | 54 | 18 | 68 | 37.2 | 962 | 22 | 1,180 | + | + | + |
6 | dSSc | ATA PM-Scl | 9.3 | 56 | 29 | 36 | 66 | 22.4 | 122 | 99 | 254 | + | + | + |
7 | dSSc | ATA U3-RNP | 16.2 | 54 | 14 | 21 | 68 | 17.8 | 109 | 52 | 271 | + | + | + |
8 | lSSc | ACA | 13.6 | 50 | 16 | 19 | 64 | 24.8 | 173 | 96 | 40 | + | + | ND |
9 | dSSc | 0 | 11.6 | 14 | 15 | 14 | 69 | 9.1 | 57 | 20 | 28 | + | + | ND |